Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect Study of AZD5055
NCT05630677Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AZD5055 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration time curve from time 0 to infinity, Area under the concentration time curve from time 0 to the last quantifiable concentration and 1 more. Started Nov 2022; status: completed.
02
Drugs
AZD5055
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05630677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630677.